Michael Catelani is President & COO +1 at Anixa Biosciences Inc (ANIX). They have made 7 open-market trades across 2 companies since 2018, most recently 2026-09-30.
CIK 0001689394
7 open-market purchases totalling $102K since 2018, never a sale. Across 5 scored buys the stock is up 20.8% at ninety days, and 26.4 points ahead of the S&P over the same stretch.
6 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ANIX | 50,000 | $134K |
| ITUS | 2,250 | $10K |
| Total | $144K |
Shares reported on the most recent Form 4, priced at the 2026-09-30 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 50% | 60% | 80% |
| Avg Move | +13.1% | +13.7% | +20.8% |
| Alpha | +12.8% | +16.1% | +26.4% |
| Scored | 6 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ANIX | BUY | 2026-09-30 | 2026-09-30 | $2.84 | $16K | -2.1% | — | — |
| ANIX | BUY | 2025-01-15 | 2025-01-15 | $2.15 | $20K | +20.2% | +34.8% | +22.3% |
| ANIX | BUY | 2024-06-07 | 2024-06-07 | $2.40 | $15K | -5.0% | -12.7% | +29.2% |
| ANIX | BUY | 2023-07-20 | 2023-07-21 | $3.64 | $20K | -3.0% | -5.4% | -14.2% |
| ANIX | BUY | 2022-04-21 | 2022-04-22 | $2.66 | $15K | +33.8% | +21.0% | +33.5% |
| ANIX | BUY | 2022-04-20 | 2022-04-21 | $2.53 | $6K | +34.8% | +30.8% | +33.2% |
| ITUS | BUY | 2018-09-18 | 2018-09-19 | $4.45 | $10K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.